Literature DB >> 1536955

Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis.

K M Shannon1, J Watterson, P Johnson, P O'Connell, B Lange, N Shah, P Steinherz, Y W Kan, J R Priest.   

Abstract

Loss of constitutional heterozygosity is a common molecular feature of cancers in which inactivation of one or more tumor suppressor genes is thought to contribute to tumorigenesis. Recent evidence suggests that the gene responsible for neurofibromatosis, type 1 (NF-1), belongs to this class of heritable cancer genes. Children with NF-1 show an increased incidence of myeloid leukemia, including juvenile chronic myelogenous leukemia (JCML) and, perhaps, the myeloproliferative syndrome (MPS) associated with bone marrow monosomy 7 (Mo 7). We have investigated five children with Mo 7: three with NF-1 and two others with suggestive evidence of NF-1. Southern blotting experiments performed in four patients showed no loss of heterozygosity in bone marrow specimens using probes linked to the NF-1 locus on the long arm of chromosome 17. Both of our patients with familial NF-1 inherited the disease from their mothers, as did 14 of 19 other cases of myeloid leukemia in children with familial NF-1. Seventeen of these 21 children were boys. Myeloid leukemia developed in 12 boys and four girls who inherited NF-1 from their mothers, and in five boys who inherited the disease from their fathers. Father-to-daughter transmission was not observed. Taken together, the presence of chromosome 7 deletions in the leukemias of children with NF-1, a pattern of inheritance favoring maternal transmission of NF-1, and the marked predilection for boys to develop JCML and Mo 7 suggest a multistep mechanism of oncogenesis in which epigenetic factors might play a role. Further investigation is required to determine if the NF-1 genes in the leukemic bone marrows of these patients have acquired point mutations or small deletions.

Entities:  

Mesh:

Year:  1992        PMID: 1536955

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

Review 1.  RAS inhibitors in hematologic cancers: biologic considerations and clinical applications.

Authors:  D M Beaupre; R Kurzrock
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.

Authors:  Rebecca J Chan; Todd Cooper; Christian P Kratz; Brian Weiss; Mignon L Loh
Journal:  Leuk Res       Date:  2008-10-26       Impact factor: 3.156

3.  Frequent disruption of the Nf1 gene by a novel murine AIDS virus-related provirus in BXH-2 murine myeloid lymphomas.

Authors:  B C Cho; J D Shaughnessy; D A Largaespada; H G Bedigian; A M Buchberg; N A Jenkins; N G Copeland
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 4.  Clinical and genetic patterns of neurofibromatosis 1 and 2.

Authors:  N K Ragge
Journal:  Br J Ophthalmol       Date:  1993-10       Impact factor: 4.638

5.  Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies.

Authors:  Jasmine C Y Wong; Yan Zhang; Kenneth H Lieuw; Mary T Tran; Erna Forgo; Kelley Weinfurtner; Pilar Alzamora; Scott C Kogan; Keiko Akagi; Linda Wolff; Michelle M Le Beau; Nigel Killeen; Kevin Shannon
Journal:  Blood       Date:  2010-03-16       Impact factor: 22.113

6.  Quantitative effects of Nf1 inactivation on in vivo hematopoiesis.

Authors:  Y Zhang; B R Taylor; K Shannon; D W Clapp
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

7.  Retroviral integration at the Epi1 locus cooperates with Nf1 gene loss in the progression to acute myeloid leukemia.

Authors:  S M Blaydes; S C Kogan; B T Truong; D J Gilbert; N A Jenkins; N G Copeland; D A Largaespada; C I Brannan
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

8.  Loss of the nf1 tumor suppressor gene decreases fas antigen expression in myeloid cells.

Authors:  Kelly Hiatt; David A Ingram; Hannah Huddleston; Dan F Spandau; Reuben Kapur; D Wade Clapp
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

9.  BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction.

Authors:  Amish J Patel; Chung-Ping Liao; Zhiguo Chen; Chiachi Liu; Yong Wang; Lu Q Le
Journal:  Cell Rep       Date:  2013-12-27       Impact factor: 9.423

Review 10.  Genetic predispositions and childhood cancer.

Authors:  K Shannon
Journal:  Environ Health Perspect       Date:  1998-06       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.